Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma

Inclusion Criteria: * Age \>18 anni * Written informed consent signed Cohort A * Age \>18 years * Histologically confirmed diagnosis of relapsed/refractory classical Hodgkin lymphoma identified during induction or follow-up * Available formalin-fixed, paraffin-embedded (FFPE) biopsy at diagnosis and at the time of progression/relapse * Available plasma sample at progression (before the beginning of salvage therapy) * Available FDG-PET evaluation at study enrollment * Available clinical, laboratory, and radiologic data at diagnosis and relapse Cohort B * Diagnosis of classical Hodgkin lymphoma * Completion of first-line standard systemic treatment (chemotherapy-based or chemoradiotherapy combined modality) * Available plasma sample at the end of treatment (at least 30 days from the last chemotherapy) * Available FFPE biopsy at diagnosis * No further treatment planned * Available clinical, laboratory, and radiologic data at diagnosis and response evaluation * Patient's willingness to undergo 6 months follow-up plasma sample collection and to attend regular follow-up Cohort C * Histologically confirmed diagnosis of classical Hodgkin lymphoma * Standard treatment as per available guidelines (e.g., ESMO guidelines) * Available treatment data, response, and follow-up data * Available FFPE biopsy at diagnosis * Available FDG-PET evaluation at study enrollment Exclusion Criteria: * Patients with nodular lymphocyte predominant Hodgkin lymphoma are not eligible; all other subtypes including nodular sclerosis, lymphocyte-depleted, lymphocyte-rich, and mixed cellularity Hodgkin lymphoma may be enrolled. * Active HIV, HBV, HCV viral infection * Concomitant neoplasm not treated with a curative aim